Home » Stocks » VSTM

Verastem, Inc. (VSTM)

Stock Price: $3.32 USD -0.07 (-2.06%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $3.66 +0.34 (10.24%) Jul 29, 7:02 PM
Market Cap 582.81M
Revenue (ttm) 84.47M
Net Income (ttm) -44.77M
Shares Out 171.59M
EPS (ttm) -0.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.32
Previous Close $3.39
Change ($) -0.07
Change (%) -2.06%
Day's Open 3.38
Day's Range 3.28 - 3.43
Day's Volume 740,965
52-Week Range 1.08 - 4.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that an abstract detailing updat...

2 days ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has converted all of the...

1 week ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase ...

3 weeks ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the appointm...

1 month ago - Business Wire

These unloved cancer stocks should dramatically outperform Dogecoin over the long haul.

Other stocks mentioned: ADAP
1 month ago - The Motley Fool

Verastem (VSTM) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

1 month ago - Zacks Investment Research

Did these penny stocks slip by yesterday unnoticed? Here's 3 big gainers you may have missed The post These Penny Stocks Hit it Big Yesterday, Here's Why appeared first on Penny Stocks to Buy, Picks, Ne...

Other stocks mentioned: SB, TELL
2 months ago - PennyStocks

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced t...

2 months ago - Business Wire

The biotech's experimental cancer treatment won an important regulatory designation today.

2 months ago - The Motley Fool

The FDA has granted Breakthrough Therapy designation to Verastem Inc (NASDAQ: VSTM) for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer (LG...

2 months ago - Benzinga

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

2 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fi...

2 months ago - Business Wire

Penny stocks are back in a big way; which 3 should you watch? The post Penny Stocks Are Back; Here's 3 to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...

Other stocks mentioned: ADMA, BOXL
3 months ago - PennyStocks

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fi...

4 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

4 months ago - Business Wire

The biotech's chief medical officer has stepped down just two weeks after joining the company.

6 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

6 months ago - Business Wire

Verastem has recently raised non-dilutive capital to bring two assets into phase 2 trials. The company's lead asset has the potential to address around 30% of all cancers and be combined with other medi...

6 months ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

6 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

7 months ago - Business Wire

Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.

7 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

7 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported fin...

8 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced ne...

9 months ago - Business Wire

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

9 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced up...

10 months ago - Business Wire

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

10 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

10 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...

10 months ago - Business Wire

The biotech company reported second-quarter earnings and sold some drug development rights.

11 months ago - The Motley Fool

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...

11 months ago - Business Wire

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

11 months ago - Business Wire

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

Verastem: A Growth Story In The Biotechnology Sector

1 year ago - Seeking Alpha

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cance...

1 year ago - Business Wire

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

1 year ago - Zacks Investment Research

If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.

1 year ago - The Motley Fool

Is (VSTM) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.

1 year ago - The Motley Fool

Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.

Other stocks mentioned: AGEN, DVAX
1 year ago - The Motley Fool

Investors are excited about an upcoming conference call to discuss clinical data from patients with KRAS-mutation positive tumors.

1 year ago - The Motley Fool

Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

1 year ago - Zacks Investment Research

Verastem Oncology: An Undervalued KRAS Oncology Play

1 year ago - Seeking Alpha

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, AMRX, MRTX, VKTX
1 year ago - The Motley Fool

Is (VSTM) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Verastem has been struggling lately, but the selling pressure may be coming to an end soon.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).

1 year ago - Zacks Investment Research

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactin... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2012
CEO
Brian Stuglik
Employees
48
Stock Exchange
NASDAQ
Ticker Symbol
VSTM
Full Company Profile

Financial Performance

In 2020, Verastem's revenue was $88.52 million, an increase of 407.08% compared to the previous year's $17.46 million. Losses were -$67.73 million, -54.61% less than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Verastem stock is "Buy." The 12-month stock price forecast is 6.00, which is an increase of 80.72% from the latest price.

Price Target
$6.00
(80.72% upside)
Analyst Consensus: Buy